skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV

Authors:
; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; ; more »; ; ; ; ; « less
Publication Date:
Research Org.:
Argonne National Lab. (ANL), Argonne, IL (United States). Advanced Photon Source (APS)
Sponsoring Org.:
NIHNIAIDOTHER
OSTI Identifier:
1330880
Resource Type:
Journal Article
Resource Relation:
Journal Name: Nature Structural & Molecular Biology; Journal Volume: 23; Journal Issue: 9
Country of Publication:
United States
Language:
ENGLISH

Citation Formats

Joyce, M. Gordon, Zhang, Baoshan, Ou, Li, Chen, Man, Chuang, Gwo-Yu, Druz, Aliaksandr, Kong, Wing-Pui, Lai, Yen-Ting, Rundlet, Emily J., Tsybovsky, Yaroslav, Yang, Yongping, Georgiev, Ivelin S., Guttman, Miklos, Lees, Christopher R., Pancera, Marie, Sastry, Mallika, Soto, Cinque, Stewart-Jones, Guillaume B. E., Thomas, Paul V., Van Galen, Joseph G., Baxa, Ulrich, Lee, Kelly K., Mascola, John R., Graham, Barney S., and Kwong, Peter D. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. United States: N. p., 2016. Web. doi:10.1038/nsmb.3267.
Joyce, M. Gordon, Zhang, Baoshan, Ou, Li, Chen, Man, Chuang, Gwo-Yu, Druz, Aliaksandr, Kong, Wing-Pui, Lai, Yen-Ting, Rundlet, Emily J., Tsybovsky, Yaroslav, Yang, Yongping, Georgiev, Ivelin S., Guttman, Miklos, Lees, Christopher R., Pancera, Marie, Sastry, Mallika, Soto, Cinque, Stewart-Jones, Guillaume B. E., Thomas, Paul V., Van Galen, Joseph G., Baxa, Ulrich, Lee, Kelly K., Mascola, John R., Graham, Barney S., & Kwong, Peter D. Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV. United States. doi:10.1038/nsmb.3267.
Joyce, M. Gordon, Zhang, Baoshan, Ou, Li, Chen, Man, Chuang, Gwo-Yu, Druz, Aliaksandr, Kong, Wing-Pui, Lai, Yen-Ting, Rundlet, Emily J., Tsybovsky, Yaroslav, Yang, Yongping, Georgiev, Ivelin S., Guttman, Miklos, Lees, Christopher R., Pancera, Marie, Sastry, Mallika, Soto, Cinque, Stewart-Jones, Guillaume B. E., Thomas, Paul V., Van Galen, Joseph G., Baxa, Ulrich, Lee, Kelly K., Mascola, John R., Graham, Barney S., and Kwong, Peter D. 2016. "Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV". United States. doi:10.1038/nsmb.3267.
@article{osti_1330880,
title = {Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV},
author = {Joyce, M. Gordon and Zhang, Baoshan and Ou, Li and Chen, Man and Chuang, Gwo-Yu and Druz, Aliaksandr and Kong, Wing-Pui and Lai, Yen-Ting and Rundlet, Emily J. and Tsybovsky, Yaroslav and Yang, Yongping and Georgiev, Ivelin S. and Guttman, Miklos and Lees, Christopher R. and Pancera, Marie and Sastry, Mallika and Soto, Cinque and Stewart-Jones, Guillaume B. E. and Thomas, Paul V. and Van Galen, Joseph G. and Baxa, Ulrich and Lee, Kelly K. and Mascola, John R. and Graham, Barney S. and Kwong, Peter D.},
abstractNote = {},
doi = {10.1038/nsmb.3267},
journal = {Nature Structural & Molecular Biology},
number = 9,
volume = 23,
place = {United States},
year = 2016,
month = 8
}
  • A safe and effective vaccine against respiratory syncytial virus (RSV) should confer protection without causing vaccine-enhanced disease. Here, using a cotton rat model, we investigated the protective efficacy and safety of an RSV combination vaccine composed of F-encoding plasmid DNA and virus-like particles containing RSV fusion (F) and attachment (G) glycoproteins (FFG-VLP). Cotton rats with FFG-VLP vaccination controlled lung viral replication below the detection limit, and effectively induced neutralizing activity and antibody-secreting cell responses. In comparison with formalin inactivated RSV (FI-RSV) causing severe RSV disease after challenge, FFG-VLP vaccination did not cause weight loss, airway hyper-responsiveness, IL-4 cytokines, histopathology, andmore » infiltrates of proinflammatory cells such as eosinophils. FFG-VLP was even more effective in preventing RSV-induced pulmonary inflammation than live RSV infections. This study provides evidence that FFG-VLP can be developed into a safe and effective RSV vaccine candidate. - Highlights: • Combined RSV FFG VLP vaccine is effective in inducing F specific responses. • FFG VLP vaccine confers RSV neutralizing activity and viral control in cotton rats. • Cotton rats with RSV FFG VLP vaccination do not show vaccine-enhanced disease. • Cotton rats with FFG VLP vaccine induce F specific antibody secreting cell responses. • Cotton rats with FFG VLP do not induce lung cellular infiltrates and Th2 cytokine.« less
  • Development of effective vaccines against highly pathogenic avian influenza (HPAI) H5N1 viruses is a global public health priority. Considering the difficulty in predicting HPAI H5N1 pandemic strains, one strategy used in their design includes the development of formulations with the capacity of eliciting broad cross-protective immunity against multiple viral antigens. To this end we constructed a replication-defective recombinant adenovirus-based avian influenza virus vaccine (rAdv-AI) expressing the codon-optimized M2eX-HA-hCD40L and the M1-M2 fusion genes from HPAI H5N1 human isolate. Although there were no significant differences in the systemic immune responses observed between the intramuscular prime-intramuscular boost regimen (IM/IM) and the intranasalmore » prime-intramuscular boost regimen (IN/IM), IN/IM induced more potent CD8{sup +} T cell and antibody responses at mucosal sites than the IM/IM vaccination, resulting in more effective protection against lethal H5N2 avian influenza (AI) virus challenge. These findings suggest that the strategies used to induce multi-antigen-targeted mucosal immunity, such as IN/IM delivery of rAdv-AI, may be a promising approach for developing broad protective vaccines that may be more effective against the new HPAI pandemic strains.« less
  • Highlights: Black-Right-Pointing-Pointer Vero cell-based HPAI H5N1 vaccine with stable high yield. Black-Right-Pointing-Pointer Stable high yield derived from the YNVa H3N2 backbone. Black-Right-Pointing-Pointer H5N1/YNVa has a similar safety and immunogenicity to H5N1delta. -- Abstract: Highly pathogenic avian influenza (HPAI) viruses pose a global pandemic threat, for which rapid large-scale vaccine production technology is critical for prevention and control. Because chickens are highly susceptible to HPAI viruses, the supply of chicken embryos for vaccine production might be depleted during a virus outbreak. Therefore, developing HPAI virus vaccines using other technologies is critical. Meeting vaccine demand using the Vero cell-based fermentation process hasmore » been hindered by low stability and yield. In this study, a Vero cell-based HPAI H5N1 vaccine candidate (H5N1/YNVa) with stable high yield was achieved by reassortment of the Vero-adapted (Va) high growth A/Yunnan/1/2005(H3N2) (YNVa) virus with the A/Anhui/1/2005(H5N1) attenuated influenza vaccine strain (H5N1delta) using the 6/2 method. The reassorted H5N1/YNVa vaccine maintained a high hemagglutination (HA) titer of 1024. Furthermore, H5N1/YNVa displayed low pathogenicity and uniform immunogenicity compared to that of the parent virus.« less